美國居民不適用 XM 服務。
N
N

Novartis

交易方向

交易者脈動

技術摘要

小時

財經新聞

Novartis AG <NVS.N> expected to post earnings of $1.70 a share - Earnings Preview

Novartis AG expected to post earnings of $1.70 a share - Earnings Preview Novartis AG NVS.N , NVS is expected to show a fall in quarterly revenue when it reports results on April 23 for the period ending March 31 2024 The Basel Basel-stadt-based company is expected to report a 11.1% decrease in revenue to $11.52 billion from $12.95 billion a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
N

Novartis AG <NOVN.S> expected to post earnings of $1.69 a share - Earnings Preview

Novartis AG expected to post earnings of $1.69 a share - Earnings Preview Novartis AG NOVN.S is expected to show a fall in quarterly revenue when it reports results on April 23 for the period ending March 31 2024 The Basel Basel-stadt-based company is expected to report a 11.1% decrease in revenue to $11.518 billion from $12.95 billion a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
N

US FDA mandates label updates on T cancer therapies

US FDA mandates label updates on CAR-T cancer therapies April 18 (Reuters) - The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called "boxed warning" to highlight the serious risk of T-cell blood cancer in patients who use these therapies. The health regulor has required related updates to other sections of the label such as warnings and precautions, postmarketing experience, patient counseling information and medicat
G
N

Weight-loss drug developer Metsera raises $290 million in funding

Weight-loss drug developer Metsera raises $290 million in funding By Pratik Jain April 18 (Reuters) - Weight-loss drug developer Metsera has raised $290 million in funding, led by biotech investor ARCH Venture Partners as well as participation from firms such as SoftBank and Mubadala Capital, the company said on Thursday. The funding comes at a time when multiple drug companies are competing to grab a slice of the weight-loss drug market, which is estimated by analysts to reach at least $100 bil
N
P

Novartis Kesimpta® Six-Year Efficacy Data Show Substantial Benefits In Recently Diagnosed Treatment- Naïve People With Relapsing Multiple Sclerosis

BRIEF-Novartis Kesimpta® Six-Year Efficacy Data Show Substantial Benefits In Recently Diagnosed Treatment- Naïve People With Relapsing Multiple Sclerosis April 17 (Reuters) - NOVARTIS AG NOVN.S : NOVARTIS KESIMPTA® SIX-YEAR EFFICACY DATA SHOW SUBSTANTIAL BENEFITS IN RECENTLY DIAGNOSED TREATMENT- NAÏVE PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS SI
N

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明